You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 29, 2014

Food Labeling: A Recent Change in the Thai Paradigm

Informed Counsel

In response to consumers paying more attention to their dietary nutritional values, the food industry has taken steps to alter its approach to food product labeling. Labels that stipulate nutrient levels in food products (e.g., claiming low fat, high vitamin C, etc.) are now a common sight on food packaging. The Thai Food and Drug Administration (FDA) has, however, set certain criteria that must be met in order to make such nutritional claims and statements. Meanwhile, comparative claims, such as “the best,” “the most,” “the first,” etc., are prohibited, as the Thai FDA considers these claims to be difficult to prove.

The Thai FDA has issued legislation on “premium labeling,” a form of labeling that allows food producers to grade their food products, thus protecting their rights and the rights of consumers. The word “premium” on a food product label indicates that the food product possesses special qualities—qualities that the food producer must provide. Use of the word “premium” is subject to the approval of the Thai FDA. Such approval is obtained by citing evidence in support of the food’s “premium” quality (e.g., the food has been certified as organic, it has a geographical indication, or it has special ingredients). The first food products that received such approval were pasteurized milk and plain-fluid milk, both of which contain higher levels of milk protein, fat, and nonfat milk solids, as compared to other similar products.

Nutritional Labeling

Nutrition tables can be presented in three different formats: “full,” “short,” and “parallel.” The Ministry of Public Health’s Notification requires each table to contain certain information such as the amount of food per serving size, number of serving sizes per unit, nutrient content, and percentage of Thai Recommended Daily Intake (RDI) for each nutrient, per serving size, per day. A full format nutrition table must contain at least the following 15 mandatory nutrients:

  1. Total energy
  2. Energy from fat
  3. Total fat
  4. Saturated fat
  5. Cholesterol
  6. Protein
  7. Total carbohydrate
  8. Fiber
  9. Sugar
  10. Sodium
  11. Vitamin A
  12. Vitamin B1
  13. Vitamin B2
  14. Calcium
  15. Iron

However, if 8 or more of these 15 nutrients are low enough to be considered nonexistent, a short-format nutrition label can be used.

In the case that the food products must be mixed with other ingredients and/or processed according to the parallel label format, nutrition tables can be used to compare the nutritional values before and after preparation of the food product.

GDA Labeling

Obesity and related noncommunicable diseases have become global health concerns. The FDA has approached these issues by presenting nutritional information in recommended Guidelines of Daily Amounts (GDA), which aim to inform consumers of the amount of calories, sugars, fats, and sodium in food that they should be consuming daily. These guidelines are already used for some ready-to-eat foods, including fried or baked potato chips, crackers or biscuits, and wafers with fillings. These products must have nutrition and GDA labels, and must show the following statement: “Consume less and exercise for health.”

The GDA requires calories, sugars, fats, and sodium to be displayed on the front of the packaging by clearly declaring the nutrient content and the percentage of RDI per packaging unit, such as per sachet or carton. This information is shown in four cylindrical shapes. (See Fig. 2 below.)

Self-Regulating Product Labeling

On January 21, 2014, the FDA reclassified seven food products (sealed beverages, canned food, cow milk, flavored milk, fermented milk, milk products, and ice cream) as Standardized Foods. Under this category, food producers’ product labels must comply with FDA regulations and do not need label approval from the FDA. But some high-risk food products (e.g., medical foods, infant foods, modified milk for infants, weight-control foods, food additives, etc.) are still required to be submitted to and approved by the FDA for label preparation.

Which Food Labeling Requirements Have Changed?

Normally, a product label must provide the following information in Thai: (1) product name; (2) serial number; (3) importer’s or manufacturer’s name and address; (4) metric declaration of quantity; (5) ingredient list; and (6) production and expiration dates.

A noticeable change in the updated food labeling requirements is the addition of allergen information. Previously, the declaration of allergen information was on a voluntary basis. Now, it is mandatory to declare the allergen information of products that use the following ingredients:

  • Cereals that contain gluten, such as wheat, rye, spelt, or hybrid varieties, and their products;
  • Crustaceans and crustacean products;
  • Eggs and egg products;
  • Fish and fish products;
  • Peanuts, soybeans, and their products;
  • Milk and milk products (including lactose);
  • Hard-shelled nuts (such as pistachios), nuts, tree nuts (e.g., almonds, walnuts, pecans), and their products; and
  • Sulphite in concentrations of 10 mg/kg or more.

How to Comply with the Changed Regulations

Food regulations, particularly for food and nutrition labels, are becoming more dynamic and self-regulated than they have ever been in the past. Although this change in paradigm is beneficial for the food business, such autonomy means that food companies should have their labels carefully reviewed by lawyers and food consultants who have the proper technical and legislative knowledge, in order to fully comply with the law.

RELATED INSIGHTS​ 

July 13, 2026
Indonesia’s Halal Product Assurance Agency (BPJPH) has issued new regulations establishing clearer procedures for imposing administrative sanctions on businesses that violate halal product assurance requirements. BPJPH Regulation No. 2 of 2026 on the Imposition of Administrative Sanctions for Violations of Halal Product Assurance Implementation, issued on June 5, 2026, strengthens Indonesia’s halal compliance framework, as mandated under Law No. 33 of 2014 on Halal Product Assurance and Government Regulation No. 42 of 2024 on the Implementation of Halal Product Assurance. BPJPH Regulation No. 2/2026 also supports the upcoming mandatory halal compliance deadline of October 17, 2026, which will apply to a broad range of products and services, including imported food and beverages, slaughtering products and services, natural and quasi-drugs, health supplements, cosmetics, chemical and genetically engineered products, clothing and accessories, household goods, prayer equipment, stationery, and class A medical devices. Scope BPJPH is authorized to impose administrative sanctions for violations of halal product assurance requirements committed by businesses, halal inspection agencies (LPH), halal auditors, halal product process companion institutions (lembaga pendamping PPH), and halal product process companions (pendamping PPH). The head of BPJPH has authority to determine, cancel, or amend the imposition of administrative sanctions, including upon receipt of objections. This authority covers revocation of Halal Certificates (including foreign halal certificate registration numbers), withdrawal of goods from circulation, freezing of LPH operations, freezing of halal product process companion institutions, revocation of PPH companion institution registration numbers, revocation of halal auditor registration numbers, and revocation of LPH accreditation status. Administrative Sanctions Businesses may be subject to any of the following administrative sanctions: Written warning; Administrative fine; Revocation of the halal certificate, including revocation of foreign halal certificate registration numbers; and Withdrawal of goods from circulation. The regulation sets out the types of violations that may trigger these sanctions, with each
July 1, 2026
Obtaining marketing authorization is a fundamental requirement for bringing pharmaceutical products to the Thai market. Companies must navigate the Thai Food and Drug Administration’s registration procedures while also complying with post-approval pharmacovigilance obligations, licensing requirements for manufacturing and importation, data protection rules, and other regulatory requirements. This guide provides an overview of Thailand’s regulatory framework for pharmaceutical marketing authorization, including available registration pathways, review timelines, application fees, postmarketing surveillance obligations, licensing requirements, exemptions, data exclusivity, freedom of information, and parallel import considerations. It is intended as a practical reference for pharmaceutical companies, regulatory affairs professionals, and others involved in bringing medicinal products to the Thai market. Download the guide below for a concise overview of the current requirements and procedures governing pharmaceutical marketing authorization in Thailand.
June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological
June 19, 2026
For the first time, Thailand’s Food and Drug Administration (FDA) has published a consolidated list identifying all substances that have successfully passed its novel food safety evaluation process. The list is a step forward in regulatory transparency, but it also highlights a feature of the Thai regime that food companies often overlook: each approval is tied exclusively to the company that applied for it. A substance’s appearance on the list does not give other companies the green light to use it. This article examines the structure of Thailand’s novel food approval framework, the implications of applicant exclusivity, and the strategic choices it requires of food companies looking to bring novel ingredients to the Thai market. Thai FDA Food Safety Evaluation Framework Notification No. 376 of the Ministry of Public Health requires novel food substances to undergo a food safety assessment, with an exemption only for novel foods manufactured exclusively for export. The framework also encompasses “foods that do not qualify as novel foods” but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety. The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate. A notable feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements